凯莱英医药集团（天津）股份有限公司于2026年2月5日公告了截至2026年1月31日的股份变动月报表。报告期内，公司注册地在中国境内，H股于香港联合交易所上市（股票代码：06821），A股于深圳证券交易所上市（股票代码：002821）。
公司本月H股从上月底的27,553,260股增至27,834,510股，较上月增发281,250股，A股则维持在333,040,460股不变。截至1月末，公司已发行股份总数合计360,874,970股。公司未发生任何股份回购或注销活动。
根据公告，此次281,250股H股增发源于公司2026年1月26日根据H股限制性股票计划向受托人定向配发，用于满足该计划项下预期归属的激励股份。公司确认截至报告期末已符合适用的公共持股量要求，未发现违反相关上市规则的情形。
本次月报由联席公司秘书徐向科签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.